English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Treatment of experimental sepsis-induced immunoparalysis with TNF

Echtenacher, B., Urbaschek, R., Weigl, K., Freudenberg, M. A., & Männel, D. N. (2003). Treatment of experimental sepsis-induced immunoparalysis with TNF. Immunobiology, 208(4), 381-389.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Echtenacher, Bernd, Author
Urbaschek, Renate, Author
Weigl, Karin, Author
Freudenberg, Marina A.1, Author           
Männel, Daniela N., Author
Affiliations:
1Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society, ou_2243647              

Content

show
hide
Free keywords: -
 Abstract: Following a severe septic abdominal infection induced by sublethal cecal ligation and puncture (CLP) in mice, a phase of depressed immune reactivity occurred two days after CLP characterized by a reduced capacity to produce TNF. To determine whether this reduced TNF production causes immunoparalysis as determined by increased susceptibility to bacterial infection and whether therapeutic TNF substitution can be beneficial during this phase, a super-infection with Salmonella enterica Serovar typhimurium or Listeria monocytogenes was induced two days after sublethal CLP. After CLP a state of true immunoparalysis developed during which Salmonella or Listeria super-infection led to increased lethality paralleled by increased bacterial numbers in spleens and livers. Injection of recombinant human TNF before or at the time of super-infection conferred protection to Salmonella but not to Listeria. In the latter case, the infection mortality was even enhanced. Thus, super-infection during the state of sepsis-induced immunoparalysis leads to increased lethality. TNF substitution during this state of immunoparalysis can be beneficial or deleterious, depending on the location of TNF activity in the animal, timing of TNF administration, or the type of super-infection. These results demonstrate that impaired TNF production capacity can account for some aspects of immunoparalysis, however, diagnostic parameters are required for a safe TNF substitution therapy.

Details

show
hide
Language(s): eng - English
 Dates: 2003
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: eDoc: 125037
ISI: 000188170300003
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Immunobiology
  Alternative Title : Immunobiol.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 208 (4) Sequence Number: - Start / End Page: 381 - 389 Identifier: ISSN: 0171-2985